Under the terms of the agreement, the CRO will use OmniComm’s TrialOne eClinical solution to automate early phase studies at one of its U.S.-based clinical research units.

The global CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase I clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase I clinics.

TrialOne streamlines and automates key processes for early phase clinics, which drive efficiencies and reduce timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time Bedside Data Collection (BDC), direct data capture from devices, sample processing automation and data processing. The automation reduces workload on clinic staff and improves the clinical trial experience for volunteers. The browser-based, tablet-compatible system provides an advanced platform for automating clinic operations, complies with FDA 21 CFR Part 11, and supports data standards such as CDISC for faster and easier exporting and reporting of data.

“Each new contract documents TrialOne’s position as the market-leading eSource solution for Phase I clinics,” said Kuno van der Post, Ph.D., OmniComm’s chief commercial officer. “We’re excited to continue building our partnership with this leading CRO.”